Abstract:Choroidal neovascularization (CNV) is the leading cause of vision loss in many blinding diseases, but current antiangiogenic therapies with invasively intravitreal injection suffer from poor patient compliance and a rate of devastating ocular complications. Here, we develop an alternative antiangiogenic agent based on hybrid cell-membrane-cloaked nanoparticles for noninvasively targeted treatment of CNV. The retinal endotheliocyte membrane coating provides as-fabricated nanoagents with homotypic targeting capability and binding ability to the vascular endothelial growth factor. The fusion of red blood cell membranes protects the hybrid membrane-coated nanoparticles from phagocytosis by macrophages. In a laser-induced wet age-related macular degeneration mouse model, a significantly enhanced accumulation is observed in CNV regions after intravenous delivery of the hybrid membrane-coated nanoparticles. Moreover, an excellent therapeutic efficacy is achieved in reducing the leakage and area of CNV. Overall, the biomimetic antiangiogenic nanoagents provide an effective approach for noninvasive treatment of CNV.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsnano.1c00680?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsnano.1c00680</a>.Confirmation of complete hybrid membrane coating onto PLGA nanoparticle cores (Figure S1); long-term stability of [RBC-REC]NPs (Figure S2); self-recognition capability of RECNPs and [RBC-REC]NPs in vitro (Figure S3); targeting affinity to angiogenic endothelial cells in vitro (Figure S4); macrophage uptake of nanoparticles in vitro (Figure S5); biodistribution of nanoparticles in vivo (Figure S6); representative fundus photographs in the day 7 (Figure S7); active-targeting capability of [RBC-REC]NPs in CNV (Figure S8); ability of [RBC-REC]NPs in suppressing endothelial cell migration in vitro (Figure S9); cytotoxic assessment to different ocular cells (Figure S10); biosafety assessment of as-fabricated nanoparticles (Figure S11) (<a class="ext-link" href="/doi/suppl/10.1021/acsnano.1c00680/suppl_file/nn1c00680_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Reactive Oxygen Species Responsive Supramolecular Prodrug Eyedrops for the Treatment of Choroidal Neovascularization

Nanoparticles in the Ocular Drug Delivery

Clickable Corneal Neovascularization Therapy with ROS-Responsive Polydopamine Silica Nanoparticles Loaded with Fenofibrate

A Synergistic Therapy with Antioxidant and Anti‐VEGF: Towards Its Safe and Effective Elimination for Corneal Neovascularization

Targeted Noninvasive Treatment of Choroidal Neovascularization by Hybrid Cell-Membrane-Cloaked Biomimetic Nanoparticles

Multifunctional nano-in-micro delivery systems for targeted therapy in fundus neovascularization diseases

Light‐Activated Anti‐Vascular Combination Therapy against Choroidal Neovascularization

Dexamethasone-loaded ROS stimuli-responsive nanogels for topical ocular therapy of corneal neovascularization

Red Light‐Triggered Anti‐Angiogenic and Photodynamic Combination Therapy of Age‐Related Macular Degeneration (Adv. Sci. 31/2023)

Targeted Long-term Noninvasive Treatment of Choroidal Neovascularization by Biodegradable Nanoparticles

Highly effective corneal permeability of reactive oxygen species-responsive nano-formulation encapsulated cyclosporine a for dry eye management

C176-loaded and Phosphatidylserine-Modified Nanoparticles Treat Retinal Neovascularization by Promoting M2 Macrophage Polarization

“One Stone and Two Birds” Strategy to Treat Neovascular Age-Related Macular Degeneration by a Novel Retinoid Drug, EYE-101

Neovascularization-directed bionic eye drops for noninvasive renovation of age-related macular degeneration

Nanoparticle-mediated corneal neovascularization treatments: Toward new generation of drug delivery systems

Topical ocular delivery to laser-induced choroidal neovascularization by dual internalizing RGD and TAT peptide-modified nanoparticles

Macromolecular Platform with Super-Cation Enhanced Trans-Cornea Infiltration for Noninvasive Nitric Oxide Delivery in Ocular Therapy

Development of nanodrug-based eye drops with good penetration properties and ROS responsiveness for controllable release to treat fungal keratitis

Verteporfin-mediated on/off photoswitching functions synergistically to treat choroidal vascular diseases

Dual-ROS-scavenging and dual-lingering nanozyme-based eye drops alleviate dry eye disease

Cu-Doping Layered Double Hydroxides Nanozyme Integrated with Nitric Oxide Donor for Enhanced Antioxidant Therapy in Retinopathy